Wendy Beall
Family · Grantsville, WVNPI 1629325519
Payments from drug & device makers
Across 113 payments — averaging $15.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$700
- AbbVie$249
- Lilly USA, LLC$122
- AstraZeneca$109
- Mylan Specialty L.p.$96
- Novartis$65
- plus $415 from 11 others
What the payments were for
- Food & beverage$1,74699%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 52 | $700 |
| AbbVie | 12 | $249 |
| Lilly USA, LLC | 8 | $122 |
| AstraZeneca | 6 | $109 |
| Mylan Specialty L.p. | 6 | $96 |
| Novartis | 4 | $65 |
| Amarin Pharma, Inc. | 4 | $65 |
| Boehringer Ingelheim | 4 | $58 |
| Johnson & Johnson | 3 | $57 |
| Abbott | 3 | $53 |
| Amgen | 3 | $51 |
| GSK | 3 | $44 |
| Viatris Specialty LLC | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Pfizer | 1 | $13 |
| Merck | 1 | $13 |
How this compares
$1,758 in reported general payments places this provider in the 75th percentile of 1,507 family providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 118 | $155,064 |
| MounjaroTirzepatide | 58 | $99,814 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $64,424 |
| OzempicSemaglutide | 32 | $59,476 |
| TrulicityDulaglutide | 26 | $55,760 |
| RybelsusSemaglutide | 16 | $39,653 |
| JanuviaSitagliptin Phosphate | 20 | $23,157 |
| EliquisApixaban | 19 | $21,959 |
| LinzessLinaclotide | 15 | $19,319 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $18,514 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $18,369 |
| MyrbetriqMirabegron | 16 | $18,300 |
| Spiriva RespimatTiotropium Bromide | 13 | $12,651 |
| Levemir FlexpenInsulin Detemir | 14 | $7,275 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $6,763 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $58 | $167,716131 claims |
| Lilly USA, LLCMounjaro, Trulicity | $122 | $155,57484 claims |
| Novo NordiskOzempic, Rybelsus | $700 | $99,12948 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $109 | $25,13227 claims |
| MerckJanuvia | $13 | $23,15720 claims |
| PfizerEliquis | $13 | $21,95919 claims |
| AbbVieLinzess | $249 | $19,31915 claims |
| GSKTrelegy Ellipta | $44 | $18,51411 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $1,47812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,507 family providers in West Virginia.
Other family in Grantsville
- Ashley ComerCharleston$213K
- Dana CruseParkersburg$109K
- Sarah KnightCharleston$99K
- Star RoeBarboursville$55K
- Angela SettleCharleston$51K
- Amber DuncanCross Lanes$44K
- Jennifer FieldsHuntington$32K
- Gina LatheyScott Depot$31K
- Jodi BillerScott Depot$29K
- Misty BareboHuntington$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.